STRONGBRIDGE BIOPHARMA plc Proceeds from Common Stock Issued
STRONGBRIDGE BIOPHARMA plc reported Proceeds from Common Stock Issued of $28.60 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2021-03-03
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for the quarter ending 2020-12-31 was $5.48M.
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for the quarter ending 2018-12-31 was $8.60M, a 63.27% decline year-over-year.
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for the quarter ending 2018-09-30 was $0.00.
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for the quarter ending 2018-06-30 was $0.00.
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for fiscal 2020 was $28.60M.
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for fiscal 2018 was $42.10M, a 59.58% increase from fiscal 2017.
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for fiscal 2017 was $26.38M, a 18.31% decline from fiscal 2016.
- STRONGBRIDGE BIOPHARMA plc proceeds from issuance of common stock for fiscal 2016 was $32.30M.
| Period end | Proceeds from Issuance of Common Stock 0 month | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $28.60M 10-K · filed 2021-03-03 | ||||||
| 2020-09-30 | $23.12M 10-Q · filed 2020-10-29 | |||||||
| 2018-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $8.60M derived: sum of 2 quarters · filed 2021-03-03 | $8.60M derived: sum of 3 quarters · filed 2021-03-03 | $42.10M 10-K · filed 2021-03-03 | $33.51M 10-K · filed 2019-02-27 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $33.51M 10-Q · filed 2019-11-07 | $56.91M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $33.51M 10-Q · filed 2019-07-31 | $56.91M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2018-03-31 | $33.51M 10-Q · filed 2019-05-01 | $56.91M derived: sum of 2 quarters · filed 2020-02-28 | ||||||
| 2017-12-31 | $23.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $26.38M 10-K · filed 2020-02-28 | ||||||
| 2017-09-30 | $2.98M 10-Q · filed 2018-10-31 | |||||||
| 2016-12-31 | $32.30M 10-K · filed 2019-02-27 | |||||||
| 2015-12-31 | $410.00K derived: 20-F 12 month − 6-K 9 month · filed 2016-03-24 | $43.00K derived: sum of 2 quarters · filed 2016-12-30 | $32.59M derived: sum of 3 quarters · filed 2016-12-30 | $58.34M 20-F · filed 2016-03-24 | ||||
| 2015-09-30 | -$367.00K derived: 6-K 9 month − 6-K 6 month · filed 2016-12-30 | $32.18M derived: sum of 2 quarters · filed 2016-12-30 | $57.93M 6-K · filed 2016-12-30 | |||||
| 2015-06-30 | $32.60M 20-F · filed 2016-03-24 | $32.60M 20-F · filed 2017-04-04 | $32.54M derived: 6-K 6 month − 6-K 3 month · filed 2016-12-30 | $58.30M 6-K · filed 2016-12-30 | ||||
| 2015-03-31 | $25.75M 6-K · filed 2016-05-17 | |||||||
| 2015-02-28 | $25.80M 20-F · filed 2017-04-04 | |||||||
| 2015-02-10 | $25.80M 20-F · filed 2016-03-24 | |||||||
| 2014-12-31 | $10.20M 20-F · filed 2016-03-24 | $10.19M 20-F · filed 2016-03-24 | ||||||
| 2013-12-31 | $14.92M 20-F · filed 2016-03-24 |